(Total Views: 373)
Posted On: 02/24/2021 12:02:14 PM
Post# of 153963
Back in fantasyland about quickly building CytoDyn into a significant biotech once Covid revenue (and market cap) allows us to pursue multiple indications in parallel.
I mentioned that, with limited internal capabilities and with the huge number of indications potentially to test, buying out a great CRO could quickly bring CYDY the scale and skills they need.
This article notes that CRO's #5 and #6 (worldwide) just combined in a $12b deal.
https://endpts.com/in-the-biggest-cro-takeove...ical-work/
I mentioned that, with limited internal capabilities and with the huge number of indications potentially to test, buying out a great CRO could quickly bring CYDY the scale and skills they need.
This article notes that CRO's #5 and #6 (worldwide) just combined in a $12b deal.
https://endpts.com/in-the-biggest-cro-takeove...ical-work/
(2)
(0)
